New Harbor Financial Group Lowers stake in Amgen (AMGN)

Amgen (AMGN) : New Harbor Financial Group reduced its stake in Amgen by 7.69% during the most recent quarter end. The investment management company now holds a total of 48 shares of Amgen which is valued at $7,886 after selling 4 shares in Amgen , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Amgen makes up approximately 0.01% of New Harbor Financial Group’s portfolio.

Other Hedge Funds, Including , Private Trust Co Na boosted its stake in AMGN in the latest quarter, The investment management firm added 488 additional shares and now holds a total of 3,636 shares of Amgen which is valued at $597,358. Amgen makes up approx 0.15% of Private Trust Co Na’s portfolio.Jacobs Coca boosted its stake in AMGN in the latest quarter, The investment management firm added 803 additional shares and now holds a total of 38,586 shares of Amgen which is valued at $6,494,410. Amgen makes up approx 1.46% of Jacobs Coca’s portfolio.Hudson Valley Investment Advisors Inc Adv boosted its stake in AMGN in the latest quarter, The investment management firm added 326 additional shares and now holds a total of 8,789 shares of Amgen which is valued at $1,479,277. Amgen makes up approx 0.46% of Hudson Valley Investment Advisors Inc Adv’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in AMGN by selling 105,960 shares or 9.02% in the most recent quarter. The Hedge Fund company now holds 1,069,080 shares of AMGN which is valued at $178,792,939. Amgen makes up approx 0.73% of Bnp Paribas Arbitrage Sa’s portfolio.Beacon Financial Group boosted its stake in AMGN in the latest quarter, The investment management firm added 2,834 additional shares and now holds a total of 4,339 shares of Amgen which is valued at $725,654. Amgen makes up approx 0.15% of Beacon Financial Group’s portfolio.

Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.